RELX Group Is a Provider of Information and Analytics
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
RSPO Letterhead
EB 02-08 Minutes of Executive Board Meeting Date : 27 May 2008 Venue : Teleconference Start time : 0800 (UK), 0900 (Nl), 1400 (Ina), 1500(My) Attendees: Apologies: 1. Derom Bangun ( GAPKI) 2. Paul Norton (HSBC Malaysia) 1. Johann Zueblin (Migros) 3. Ian McIntosh (AAK) 2. Tim Stephenson ( AAK) 4. Christophe Liebon (Intertek) 3. Simon Lord ( Kulim Malaysia Bhd 5. Don Grubba ( IOI) ) 6. Johan Verburg (Oxfam) 4. Tony Lass ( Cadbury 7. Jan Kees Vis ( Unilever) – Chair Schweppes) 8. Chew Jit Seng (MPOA) 5. Fitrian Adrianshah (WWF- 9. Mamat Salleh (MPOA) Indonesia) 10.MR Chandran (RSPO EB Advisor) 6. Matthias Diemer ( WWF – 11.Thomas Barano ( WWF- Indonesia) Switzerland) 12.Robert Keller ( MIGROS) 7. Mohd Nor Kailany ( Felda) 13.Rudy Lumuru ( Sawit Watch) 8. Samantha Lacey ( CIS) 14.Chong Wei Kwang ( HSBC Malaysia) 9. Darrel Webber ( WWF- Malaysia) 15.Vengeta Rao (VR, Secretariat) 10.Didiek Hajar Gunadi (GAPKI) 16.Desi Kusumadewi ( RILO) AGENDA 1. Introduction and RSPO Antitrust laws 2. Confirmation of minutes of EB 01-08 3. Secretariat 3.1 Accounts & finances 3.1.1 Update on RSPO Accounts to end March 2008 3.1.2 Update on RSPO Sdn Bhd Accounts to end March 2008 3.2 Secretariat updates 3.2.1 Update from Secretary General including RILO matters 4. Membership 4.1 Outstanding/defaulting RSPO Members 4.2 Grievances 4.3 Outstanding Membership applications 4.4 Revised membership application procedures and flowchart 5. Executive Board matters 5.1 Welcome New Members / Alternates / Changes 5.2 EB Retailers seat 5.3 Approval of Ina – NI 5.4 Approval of CBs – PT Mutu Agung (Ina), PT TUV Nord (Ina) 5.5 RT6 theme, delegates fees, exhibition rentals and sponsorships 5.6 RSPO FAQ on C7.3 – cut off date 6. -
Sciencedirect Empowering Researchers at Every Step
ScienceDirect Empowering researchers at every step Training ScienceDirect for Institut Teknologi Bandung By Ujang Sanusi Customer Consultant ELSEVIER INDONESIA | 2 Elsevier is a world-leading Science, Health & Technology Information Provider CONTENT PROVISION ‘E’ CONTENT PROVISION RESEARCH MGMT SEARCH & DISCOVERY /PROMOTION TOOLS Niels Louis Alexander Albert George F. John C. Roger D. Craig C Mello Bohr Physics Pasteur Fleming Einstein Smoot Mather Kornberg Medicine (Chemistry) Medicine Physics Physics Physics Chemistry 2 | 3 Elsevier is engaging across the research workflow ScienceDirect – Extensive Multi-disciplinary Full-Text Database ScienceDirect is the largest online journal platform in the world with more than 2,500 journals in 24 subject areas owned and published by Elsevier and more than 33,000 eBooks. • Publishes over 25% of the world’s full-text scientific journals with several high- profile journal titles such as Cell, The Lancet and Tetrahedron • Over 13,859,000 articles are available online • It is also the most referenced journal platform in the world with an average of 25% citations coming from journals on ScienceDirect • Over 250,000 articles on ScienceDirect are open access Elsevier is the top scientific content provider of vital interdisciplinary information essential across industries and disciplines Scientific Research Articles Published Multi-disciplinary content Env Earth SciencesSciences #1 Global Provider ELS Life Sciences* 25% Soc Sciences Publish 25% of world’s journal articles Math & 2,500 active journals Comp -
WTM Means Business
Exhibit at ® WTM London 6-8 Nov 2017 WTM Means Business WTM London 2016 Meet the world's attracted more than travel buyers in 51,000* 3 days travel professionals 6% increase in visitors in 2016* Book your stand today at london.wtm.com Organised by Discover the world at World Travel Market London 2017 Staged annually, World Travel Market London is the leading global event for the travel industry. It is a unique opportunity for the whole global travel trade to meet, network, negotiate and conduct business under one roof. Generate new Network with key Develop new and sales leads decision makers existing relationships Launch new products Increase brand awareness Gather market intelligence WTM London Attendance Exhibition Stands More than Travel Trade Professionals Main Stand Holders 665 & Buyers 31927 Stand Sharers 3864 Media 2976 Total Exhibiting Companies 4529 £2.8 Students 1445 Ministers & Aides 125 Exhibitor Personnel 14933 billion Total Attendance 51406 of new business WTM London 2016 Travel Trade Professionals generated at WTM & Buyers Areas of Interest London 2016** Accommodation 13361 Meetings Industry 2032 Adventure Travel 5542 Press / Media Services 1622 Airline Ground Handling Services 2216 Private Travel Services 3000 Associations 2435 Ticketing Agency 2093 Business & Financial Services 1835 Tour Operator 11284 Business Travel Management Services 3954 Tourism Organisation 246 Consulting Services 1861 Tourist Attraction and Entertainment Services 3126 Destination Management Services (DMC) 6706 Transport Services 3670 Education Establishment -
Newsletternewsletter Volume 1 ■ Number 41 ■ Decemberapril 2003 2003
newsletternewsletter Volume 1 ■ Number 41 ■ DecemberApril 2003 2003 Welcome In this Issue FEATURES Dear Colleagues, Scholarly Publishing: 12 Observations on the In the transition from the print to the electronic world, technology has Current Situation and Challenges for descended upon the library like a tsunami. Librarians have labored long the Future ..............................................................2-3 and hard to create and be steered by a clear sense of mission in this new age, rather than simply being swept along by the technological wave. Library Vision of the Future: University of Rochester Libraries — There have been enormous challenges in understanding the potential of Geoff Adams the new technology and how to harness it to a needs-driven environment. Focusing on Users, Hiding Technology ............4 Fundamental questions have even been raised about the very value of traditional libraries in this The Future of Librarianship: A View From a new environment, and librarians continue to wrestle with what their future role in the scientific and School of Library and Information Science ......5-6 academic communities will be. Libraries Look to the Future: As a member of these communities Elsevier is equally affected. This highly dynamic environment Place and Space, Physical and Virtual, presents both great challenges and great opportunities. In the course of the last few years we have Where are Libraries Headed? ................................7 seen production, pricing and packaging models from the print journal world change out of all recognition to accommodate the needs of the new digital environment. We have seen the emergence of e-publishing CENTER OF ATTENTION environments such as PUBMED, JSTOR, and most recently the Open Access movement. -
Intertek Annual Report 2008
FC1 Intertek Group plc Annual Report 2008 Report Annual Bringing competitive advantage to business Annual Report 2008 IFC2 Contents 01 Financial Highlights 02 At a Glance 04 Chairman’s Statement Directors’ Report – Business Review 06 Chief Executive Officer’s Review 09 Operating Review 23 Chief Operating Officer’s Review 24 Financial Review 28 Risks and Uncertainties Directors’ Report – Governance 32 Board of Directors 34 Intertek Operations Committee 36 Corporate Governance Report 42 Remuneration Report 56 Other Statutory Information 58 Statement of Directors’ Responsibilities 59 Corporate Social Responsibility Report Financial Statements 66 Independent Auditors’ Report 68 Consolidated Income Statement 69 Consolidated Balance Sheet 70 Consolidated Statement of Cash Flows 71 Consolidated Statement of Recognised Income and Expense 72 Notes to the Financial Statements 112 Intertek Group plc Company Balance Sheet 113 Notes to the Company Financial Statements Shareholder Information 116 Corporate and Shareholder Information 117 Financial Calendar and Contact Information Cautionary statement This Annual Report contains certain forward- looking statements with respect to the financial condition, results, operations and business of Intertek Group plc. These statements and forecasts involve risk and uncertainty because they relate to events and depend upon circumstances that will occur in the future. There are a number of factors that could cause actual results or developments to differ materially from those expressed or implied by these forward-looking -
RELX Group Teach-In
RELX Group Teach-In Thursday, 9th November 2017 RELX Group Teach-In Thursday, 9th November 2017 Welcome Colin Tennant Head of Investor Relations, RELX Group Opening remarks My name is Colin Tennant. I am the Head of Investor Relations at RELX Group. I have three things to do today. First is to welcome everybody. So, welcome, everybody. Second is just a little bit of housekeeping. If the fire alarm does go off during this presentation, you'll be leaving the way you came in. There will be people with fluorescent jackets to help you find the exit. Hopefully, that won't happen. And the final thing I need to do is to introduce the host for today's presentation, Chet Burchett, the Chief Executive of Reed Exhibitions, who is going to lead you through all we are going to cover for today. So, Chet over to you. Overview of Reed Exhibitions Chet Burchett Chief Executive Officer, Reed Exhibitions My Background Thank you, Colin. Good afternoon. As Colin notes, I am, indeed, Chet Burchett. I have been Chief Executive for Reed Exhibitions since 2015. I have been with the company for almost 14 years. I joined in February 2004 as President of North America. I came over from Burson-Marsteller, one of the WPP's global public relations agencies, where I had been serving as Chief Executive for their US business. Then, my role expanded for Reed to President of the Americas when I took on responsibility for our South American business which, at the time, was a small operation in Argentina and a few shows in Brazil. -
In February 2013, Glaxosmithkline (GSK) Announced a Commitment To
In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The following guiding principles have been applied to the disclosure: Information will be excluded in order to protect the privacy of patients and all named persons associated with the study Patient data listings will be completely removed* to protect patient privacy. Anonymized data from each patient may be made available subject to an approved research proposal. For further information, please see the Patient Level Data section of the GSK Clinical Study Register. Aggregate data will be included; with any direct reference to individual patients excluded *Complete removal of patient data listings may mean that page numbers are no longer consecutively numbered Document Name RH205051 Synopsis Type Version Document Identifier Effective Date eldo_controlled 1.0; CURRENT; Most-Recent; Effective 090032d580d18c62 Reason For Issue Synopsis Report Study Number 205051 Study Title A Study to Investigate the Ant imicrobial Activity of two Test toothpastes in a Plaque Glycolysis and Regrowth Model. Test Product(s) Test toothpaste containing 0.6% w/w zinc chloride and 0.1% w/w isopropylmethylpheno l (IPMP) and 1426ppm fluoride as sodium fluoride. Indication Ant imicrobial activity Phase Not Applicable Authors: Clinical Operations PPD , HND BioStatistics PPD , BSc, MSc Clinical Research PPD , BS Approvers: Clinical Operations PPD , PhD BioStatistics PPD , BSc, CStat Clinical Research PPD , BSc, MSc, CStat Copyright: GlaxoSmithKline. An unpublished work subject to trade secret protection. This work contains confidential and proprietary information of GlaxoSmithKline and should not be copied, circulated, or distributed to persons not employed by GlaxoSmithKline unless specifically authorized. -
RELX Group Annual Reports and Financial Statements 2015
Annual Reports and Financial Statements 2015 Annual Reports and Financial Statements 2015 RELX Group is a world-leading provider of information and analytics for professional and business customers across industries. We help scientists make new discoveries, lawyers win cases, doctors save lives and insurance companies offer customers lower prices. We save taxpayers and consumers money by preventing fraud and help executives forge commercial relationships with their clients. In short, we enable our customers to make better decisions, get better results and be more productive. RELX PLC is a London listed holding company which owns 52.9 percent of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1 percent of RELX Group. Forward-looking statements The Reports and Financial Statements 2015 contain forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended. These statements are subject to a number of risks and uncertainties that could cause actual results or outcomes to differ materially from those currently being anticipated. The terms “estimate”, “project”, “plan”, “intend”, “expect”, “should be”, “will be”, “believe”, “trends” and similar expressions identify forward-looking statements. Factors which may cause future outcomes to differ from those foreseen in forward-looking statements include, but are not limited to competitive factors in the industries in which the Group operates; demand for the Group’s products and services; exchange rate fluctuations; general economic and business conditions; legislative, fiscal, tax and regulatory developments and political risks; the availability of third-party content and data; breaches of our data security systems and interruptions in our information technology systems; changes in law and legal interpretations affecting the Group’s intellectual property rights and other risks referenced from time to time in the filings of the Group with the US Securities and Exchange Commission. -
Beijing Hits Back After US Treasury Labels China a Currency Manipulator
BUSINESS WITH PERSONALITY HEARTBREAK BLAST FROM THE PAST HOTEL WHEN A NEW SUPERCHARGED HOLIDAYS GO £90K CLASSIC MINI P18 WRONG P17 WEDNESDAY 7 AUGUST 2019 ISSUE 3,430 CITYAM.COM FREE CRYIN’ KING Disney investors GOVE POINTS tearful despite box office success THE FINGER CATHERINEAT NEILAN BRUSSELSthe backing of the Commons. ratification of the withdrawal agree- “We can’t have a deal that doesn’t ment, or further extension or revoca- @CatNeilan command the confidence of the gov- tion of Article 50... [I am] certainly not THE UK has accused the EU of refusing ernment, the parliament and the fatalistic about that. to budge on Brexit negotiations and in- country and that is why we have been “Our position is that the withdrawal sisted the bloc “must change its clear with the European Union that agreement, including the backstop is stance” if a no-deal exit is to be dodged. we need a new approach,” he closed, but there is always room for Ireland’s Leo Varadkar yesterday responded. talks and negotiations. We have said said he was confident a no-deal Brexit “We stand ready to engage with the we can certainly make changes to the could still be avoided, despite EU to negotiate in good faith… political declaration, and we have Prime Minister Boris Johnson We will put all our energy demonstrated before to offer clarifica- stressing the UK will leave into making sure we can tions as we did at the request of Prime the European Union “do secure that good deal. Minister May in the past.” or die”, come 31 Octo- “At the moment it’s Yesterday the pound hit its lowest ber. -
5455 Wilshire Blvd, #806 . Los Angeles, CA
September 1, 2016 Erik Engstrom CEO, RELX Group 1-3 Strand London, WC2N 5JR, UK RE: ME/CFS coverage in your publication, The Lancet Dear Mr. Engstrom, On behalf of the Solve ME/CFS Initiative and as a patient with Myalgic encephalomyelitis (ME), commonly known as Chronic Fatigue Syndrome (CFS), I am writing to bring your attention to a matter of vital importance to the ME/CFS community, the PACE Trials and your publication, The Lancet. I am writing to ask that you continue the good name and reputation of The Lancet within the ME/CFS scientific community by facilitating an open discussion of the PACE trials and committing to publish an independent review of the trial data now that a First- Tier Tribunal has ordered the data to be released. As you may know, ME/CFS is a complex, neuro-immune disease with no known cause, treatment, diagnostic tool, nor cure. It is estimated that up to 20 million people worldwide are stricken with ME/CFS from ages 10 to 80 of any race, gender, or socio- economic class and this disease leaves its patients with lower quality of life scores than lung cancer, stroke, and rheumatoid arthritis. (Source: Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness IOM 2015 And, The Health- Related Quality of Life for Patients with Myalgic Encephalomyelitis / Chronic Fatigue Syndrome. PLoS One. 2015; 10(7): e0132421.Published online 2015 Jul 6.) The PACE Trials concluded, in contrast to over 4,000 other scientific publications, that this disease was psychological in nature. The Pace Trial evaluated a series of treatments which it claimed was successful in helping patients with ME/CFS. -
Introduction to Ascential Our Investment Case
INTRODUCTION TO ASCENTIAL OUR INVESTMENT CASE Clear long-term vision. Helping leading global brands connect with their customers in a data-driven world. Structural growth. Demand for information, data & analytics driven by growth of digital commerce. Market leaders. We are leaders, with a unique blend of specialisms, in the high growth areas in which we operate. Robust business model. High recurring and repeat revenue, with more than 50% revenues from digital subscription and platforms, across diverse global customer base. Attractive financial profile. Track record of high single digit revenue growth, strong margins and cash generation, supported by sound capital allocation. Introduction to Ascential 2 OUR CUSTOMER PROPOSITION Our information products and platforms support our customers to do three simple things… CREATE THE RIGHT MAXIMISE THE OPTIMISE DIGITAL PRODUCTS BRAND MARKETING COMMERCE IMPACT Know which products Know how to get Know how to execute the consumer wants maximum creativity with with excellence on the tomorrow. optimised media. winning platforms. 1. 2. 3. Introduction to Ascential 3 SEGMENTAL OVERVIEW –2019 Segment Revenue % Revenue1 Growth1 EBITDA2 Margin Business Model Advisory 10% Digital Subscriptions Product £86m 21% +8% £36m 42% & Platforms 90% Design Digital Subscriptions Advisory & Platforms 11% Marketing £136m 32% +9% £51m 37% 37% Events 52% Advisory 6% Digital Subscriptions & Sales - Platforms 94% Digital £90m 22% +21% £13m 15% Commerce Sales - Digital Subscriptions & Events Platforms 4% Non Digital £68m 16% -
VOLUME II Public School Code of 1949 Goods and Services Expenditures Fiscal Year 2017-2018
Public School Code of 1949 Goods and Services Expenditures Fiscal Year 2017-2018 VOLUME II Temple University Financial Disclosure Report Purchase of Goods and Services Contracts Notes and Definitions The following report provides the required disclosures for reporting the purchase of goods and services contracts. The University’s Banner Finance System does not include data enabling the distinction between the purchases of goods and services. Therefore, a single report is provided that includes both. Expenditures are categorized in the attached report using the following categories: General Supplies & Services: o General supplies, expendable equipment and software. Health Service Programs: o Animal lab, professional billing and other outside professional services. Insurance: o Malpractice, property, general liability, and employees insurances. Interest & Taxes: o Bond interest, real estate tax and debt service costs. Library: o Books, electronic periodicals, subscriptions and film. Professional Fees & Contracts: o Auditing, legal and collection fees and subcontracts. Property, Plant & Equipment: o Capital equipment, buildings and building improvements. Rent: o Equipment, building and office rentals. Repairs & Maintenance: o Equipment repair, maintenance of buildings and grounds. Telecommunications: o Telephone equipment, data communications and cellular services. Travel: o Travel agency fees, foreign and domestic travel expenses. Utilities: o Electric, gas, water, sewer, steam, chilled water and other miscellaneous utilities expenses. Each entry provides the category into which the purchase falls, the vendor name and address and the amount of the purchase. There is no more than one entry per vendor for a single category within a responsibility center. Purchases of goods and services in the Disclosure Report include those which equal or exceed $1,000 for each vendor from all Budgeted Operating Funds including Temple University Physicians.